Compare Amylx Pharmaceuticals Inc (AMLX) vs United Airlines Holdings Inc (UAL) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

United Airlines (UAL) trades at $129.56, up 0.34% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $59.07B in 2025 and a net income margin of 5.56%, while valuation metrics like a P/E of 12.13 suggest potential undervaluation. Recent news highlights fleet innovation focus after merger attempts failed, with analyst consensus strongly bullish.

The outlook for UAL is positive, driven by sustained travel demand and cost management, but risks include fuel price volatility and competitive pressures. With 66% of analysts rating it Buy and a consensus price target of $167.73, the stock offers upside, though investors must monitor execution on fuel cost recapture and economic sensitivity.